Gastroparesis — delayed stomach emptying without mechanical obstruction — affects an estimated 5 million Americans and has limited treatment options. The vagus nerve controls gastric motility, so when it is damaged or dysfunctional, the stomach empties slowly or not at all. Gastric electrical stimulation (GES) with the Enterra device is the primary neuromodulation therapy for refractory gastroparesis, but its mechanism is different from traditional vagus nerve stimulation. This article explains the vagal basis of gastroparesis, how GES works, and what the clinical evidence shows.
The Vagus Nerve’s Role in Gastric Motility
The vagus nerve controls stomach function through two main pathways. Efferent motor fibres from the dorsal motor nucleus of the vagus (DMV) in the brainstem project to the myenteric plexus of the stomach wall, where they release acetylcholine to stimulate smooth muscle contraction and coordinate the migrating motor complex — the pattern of peristaltic waves that moves food from the fundus through the antrum and into the duodenum. Afferent sensory fibres carry stretch, chemical, and nutrient signals from the stomach back to the brainstem, closing a feedback loop that adjusts motility in real time.
Vagal efferent fibres also release vasoactive intestinal peptide (VIP) and nitric oxide (NO) as co-transmitters alongside acetylcholine. Nitric oxide mediates gastric accommodation — the reflex relaxation of the fundus that allows the stomach to expand and receive food without a sharp rise in pressure. Impaired vagal NO signalling contributes directly to early satiety, one of the hallmark symptoms of gastroparesis.
The interstitial cells of Cajal (ICC), which serve as pacemaker cells generating the gastric slow wave (approximately 3 cycles per minute), are modulated by vagal input. Loss of ICC or loss of vagal input to ICC disrupts the coordinated slow-wave pattern and produces the dysrhythmic gastric electrical activity seen in gastroparesis.
Causes of Vagal Gastroparesis
Diabetic gastroparesis is the most common identified cause. Chronic hyperglycaemia damages vagal fibres through oxidative stress and advanced glycation end-product accumulation, progressively impairing vagal motor control of the stomach. Up to 50 percent of patients with long-standing type 1 diabetes show delayed gastric emptying on scintigraphy, though many are asymptomatic.
Post-surgical gastroparesis occurs when the vagus nerve is inadvertently damaged during fundoplication, bariatric surgery, or other upper abdominal procedures. Historically, intentional vagotomy was performed to treat peptic ulcers, and the gastric motility consequences of that procedure — documented in millions of patients — provided much of what we know about vagal control of the stomach.
Idiopathic gastroparesis, which accounts for approximately one-third of cases, often follows a viral illness and may involve vagal neuropathy or loss of ICC without an identifiable structural cause. Post-viral vagal neuropathy has received increased attention following observations of gastroparesis developing after COVID-19 infection.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- Osteopathy and visceral manipulation
- Acupuncture
- Polyvagal-informed therapy
- Somatic therapy
- HRV biofeedback
- Craniosacral therapy
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
Gastric Electrical Stimulation: The Enterra Device
The Enterra Therapy system (Medtronic) received FDA approval under a Humanitarian Device Exemption (HDE) in 2000 for gastroparesis with chronic nausea and vomiting that has not responded to medication. It is the only neurostimulation device with FDA authorisation for gastroparesis.
The device consists of a pulse generator (similar in size to a cardiac pacemaker) implanted subcutaneously in the abdominal wall, connected to two intramuscular electrodes placed in the gastric muscle along the greater curvature, approximately 10 cm proximal to the pylorus. Standard stimulation parameters are 14 Hz, 330 microsecond pulse width, and 5 mA current, delivered in short pulse trains (0.1 seconds on, 5 seconds off). The battery lasts 5 to 10 years, and replacement requires only the generator, not the electrodes.
How GES Differs from Traditional Vagus Nerve Stimulation
GES is not vagus nerve stimulation in the traditional sense. Unlike cervical VNS, which delivers electrical pulses directly to the vagus nerve trunk in the neck, GES stimulates the gastric muscle wall with high-frequency, low-energy pulses. These short-duration pulses (under 0.4 ms) do not entrain the gastric slow wave or trigger smooth muscle action potentials. Earlier attempts at true gastric pacing — using low-frequency, long-duration pulses to pace the slow wave — were largely abandoned because they consumed too much energy for an implantable device and produced inconsistent results.
The mechanism by which GES improves symptoms is not fully understood. The device does not accelerate gastric emptying in most patients, yet it reduces nausea and vomiting. Proposed mechanisms include raising the discomfort threshold to gastric distension (possibly through vagal afferent modulation), altering central processing in the thalamus and caudate nucleus, and reducing sympathovagal imbalance. Some evidence suggests the anti-nausea effect is mediated through vagal afferent pathways, though the observation that symptom improvement also occurs in patients with prior vagotomy indicates the mechanism is not exclusively vagal.
Clinical Evidence
The pivotal 2003 randomised, double-blind trial of 33 patients demonstrated fewer weekly vomiting episodes with the stimulator on versus off. Two subsequent crossover trials were negative, which the investigators attributed to a carryover effect from the open-label run-in period during which vomiting had already decreased by approximately 80 percent.
A larger 2020 randomised trial of 218 patients found vomiting reduced in 30.6 percent of patients with the device on compared with 16.5 percent with it off. The benefit was observed in both diabetic and non-diabetic patients and in patients with and without objectively delayed gastric emptying. However, quality-of-life improvement was borderline (p = 0.06), and abdominal pain and bloating did not improve significantly.
Long-term observational data show symptom benefit persisting for 5 to 10 years in more than 50 percent of patients, with overall efficacy estimates of 50 to 70 percent. Diabetic gastroparesis generally shows better response than idiopathic gastroparesis in most studies. Opioid use and pain-predominant symptoms are associated with worse outcomes.
Complications include post-implant abdominal pain, infection (6-10 percent of cases), and device explantation (approximately 1.5 percent). The device costs approximately $15,000, but studies report reduced hospitalisations and healthcare costs that offset the device cost within a few years.
Emerging Approaches
Temporary GES, using electrodes placed percutaneously or endoscopically, is being investigated as a screening tool to identify likely responders before permanent implantation. This approach allows optimisation of electrode placement and stimulation parameters on an individual basis.
Gastric peroral endoscopic myotomy (G-POEM), which cuts the pyloric sphincter muscle endoscopically, directly accelerates gastric emptying — unlike GES, which works primarily on symptoms. G-POEM has shown promising short-term results for nausea and vomiting, though long-term data are limited. Combining GES with G-POEM is being explored for patients who need both symptom relief and improved emptying.
Closed-loop gastric neurostimulation, which adjusts stimulation parameters in real time based on gastric electrical activity or symptom feedback, represents the next generation of the technology. An ongoing clinical trial (NCT06582576) is investigating the mechanisms of action of the Enterra device in greater detail, which may guide the development of more targeted stimulation protocols.
Gastroparesis is one of the most challenging consequences of vagus nerve dysfunction. To understand the full scope of vagal control over digestion, the emerging neuromodulation therapies, and the lifestyle approaches that support gastric motility, the My Vagus Nerve & Me eBook covers it comprehensively. Get My Vagus Nerve & Me eBook and learn how the vagus nerve drives your digestive system.




